Female Urogenital Diseases and Pregnancy Complications

The department is evaluating a novel therapy called 2LPAPI® to improve clearance of genital infections caused by high‑risk oncogenic HPV. The trial seeks to determine whether the new treatment can reduce the persistence of the virus over a year of follow‑up. This research supports women’s reproductive health by aiming to lower the risk of HPV‑related complications.

  • Genital HPV infection
  • Viral clearance outcomes
  • Women’s reproductive health
  • Placebo‑controlled efficacy assessment

Centrul Medical Euromed S.R.L. is coordinating the study with a multidisciplinary team to bring innovative options to patients in Bucharest.

Immune System Diseases

Researchers are testing the immune‑modulating antibody lutikizumab for its ability to relieve signs and symptoms of moderate to severe hidradenitis suppurativa. Another study measures the impact of the oral agent remibrutinib on patients with chronic inducible urticaria (CINDU), focusing on symptom reduction and quality of life improvements. Both trials aim to expand therapeutic options for conditions driven by immune dysregulation.

  • Hidradenitis suppurativa
  • Chronic inducible urticaria (CINDU)
  • Immune pathway targeting
  • Symptom control and patient wellbeing

The site’s five investigators collaborate to generate data that could reshape treatment standards for immune‑mediated skin disorders.

Skin and Connective Tissue Diseases

A phase‑3 investigation is assessing how remibrutinib influences the achievement of HiSCR50 response criteria in adults and adolescents with moderate to severe hidradenitis suppurativa. The study evaluates the drug’s safety and tolerability while aiming to provide a new therapeutic avenue for chronic inflammatory skin disease. Results are expected to inform clinical practice for managing complex dermatologic conditions.

  • Hidradenitis suppurativa
  • Inflammatory skin disease
  • HiSCR50 response measurement
  • Treatment safety and tolerability

By conducting these trials, Centrul Medical Euromed S.R.L. contributes valuable evidence to the broader field of dermatology and connective tissue research.